Antitumor activity of a new amino acid derivative, N6,N9-bis-(butyloxycarbonylaminomethyl)-L-citrulline.
Approximately 800 amino acid derivatives have been synthesized and screened in order to evaluate their antitumor activity against various transplantable rat ascites hepatomas. Among them, N6,N9-bis(butyloxycarbonylaminomethyl)-L-citrulline (A-924) was found to be highly effective against various rat ascites hepatomas. A-924, when given orally, exhibited prolongation of survival of rats implanted intravenously with ascites hepatoma cells such as AH-44, AH-66, AH-130, AH-66F, or AH-41C.
D000284:Administration, Oral; D000818:Animals; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D002956:Citrulline / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D008113:Liver Neoplasms; D008297:Male; D009374:Neoplasms, Experimental / Q000188:drug therapy; D051381:Rats
D002956:Citrulline; C015602:A 924